Novocure Ltd (NVCR NASDAQ) stock market data APIs
$16.1345
0.26(1.6%)
as of July 18, 2025
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
16.1345
Open
16.3944
High
16.603
Low
15.84
52 wk Range
14.17-34.13
Market Cap
1 807 M
Shares Outstanding
111 M
Revenue
622 M
EPS
-0.31
Beta
0.746
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 622 M
- EBITDA: -153 508 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-05
- EPS/Forecast: -0.464
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
NovoCure stock initiated with Buy rating at Ladenburg Thalmann
Investing.com - Ladenburg Thalmann initiated coverage on NovoCure Ltd. (NASDAQ:NVCR) with a Buy rating and a $30.00 price target on Tuesday. According to InvestingPro data, this target aligns with the...
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data
Investing.com - H.C. Wainwright has reiterated a Buy rating and $38.00 price target on NovoCure Ltd. (NASDAQ:NVCR) following positive trial results for its cancer treatment. Currently trading at $17.8...
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis ...
Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of NovoCure Limited (NASDAQ:NV...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
